A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma

BACKGROUND: The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-year overall survival rate is just 63% even for the pathological IA stage. Thus, in order to identify high-risk patients and facilitate clinical decision making, it is vital that we identify new progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lei, He, Huayu, Peng, Yue, Yang, Zhenlin, Gao, Shugeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465999/
https://www.ncbi.nlm.nih.gov/pubmed/34631307
http://dx.doi.org/10.7717/peerj.11911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465999/
https://www.ncbi.nlm.nih.gov/pubmed/34631307
http://dx.doi.org/10.7717/peerj.11911

Ejemplares similares